Review



s501 4 3 siderophore  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    ATCC s501 4 3 siderophore
    S501 4 3 Siderophore, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s501 4 3 siderophore/product/ATCC
    Average 92 stars, based on 3 article reviews
    s501 4 3 siderophore - by Bioz Stars, 2026-02
    92/100 stars

    Images



    Similar Products

    s501 4 3 siderophore  (ATCC)
    92
    ATCC s501 4 3 siderophore
    S501 4 3 Siderophore, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s501 4 3 siderophore/product/ATCC
    Average 92 stars, based on 1 article reviews
    s501 4 3 siderophore - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    bi 44847  (Boehringer Ingelheim)
    90
    Boehringer Ingelheim bi 44847
    Bi 44847, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bi 44847/product/Boehringer Ingelheim
    Average 90 stars, based on 1 article reviews
    bi 44847 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    y o 48 n ceim 44847 ers004249 o48 z35  (ATCC)
    92
    ATCC y o 48 n ceim 44847 ers004249 o48 z35
    Y O 48 N Ceim 44847 Ers004249 O48 Z35, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/y o 48 n ceim 44847 ers004249 o48 z35/product/ATCC
    Average 92 stars, based on 1 article reviews
    y o 48 n ceim 44847 ers004249 o48 z35 - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    n 285 ct ers004193 o48 z35 y o 48 n ceim 44847 ers004249 o48 z35 y o 48 n ceim 44833 ers004196 o48 z35 y o 48 n rki 1373 ers004176 o60 z41 o 60  (ATCC)
    92
    ATCC n 285 ct ers004193 o48 z35 y o 48 n ceim 44847 ers004249 o48 z35 y o 48 n ceim 44833 ers004196 o48 z35 y o 48 n rki 1373 ers004176 o60 z41 o 60
    N 285 Ct Ers004193 O48 Z35 Y O 48 N Ceim 44847 Ers004249 O48 Z35 Y O 48 N Ceim 44833 Ers004196 O48 Z35 Y O 48 N Rki 1373 Ers004176 O60 Z41 O 60, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/n 285 ct ers004193 o48 z35 y o 48 n ceim 44847 ers004249 o48 z35 y o 48 n ceim 44833 ers004196 o48 z35 y o 48 n rki 1373 ers004176 o60 z41 o 60/product/ATCC
    Average 92 stars, based on 1 article reviews
    n 285 ct ers004193 o48 z35 y o 48 n ceim 44847 ers004249 o48 z35 y o 48 n ceim 44833 ers004196 o48 z35 y o 48 n rki 1373 ers004176 o60 z41 o 60 - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    bi- 44847  (Boehringer Ingelheim)
    90
    Boehringer Ingelheim bi- 44847
    Bi 44847, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bi- 44847/product/Boehringer Ingelheim
    Average 90 stars, based on 1 article reviews
    bi- 44847 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    shbg sirna sc-44847  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology shbg sirna sc-44847
    (A) Stronger immunocytochemical staining of <t>SHBG</t> is shown in LNCaP and PC-3 cells treated with DHT (left panel, bar scale: 50 µm). Immunoblotting demonstrates higher levels of SHBG, Oct3/4 and Nanog expressions in the cells treated with DHT (right panel). (B) SHBG specific <t>siRNA</t> results. SHBG knockdown in both LNCaP and PC-3 cells was verified by immunoblotting (left panel); 10 nM DHT induces expressions of Oct3/4 and Nanog in the cells transfected with the siRNA control, but such an induction disappears in the cells transfected with the specific SHBG siRNA (right panel). (C) LNCaP and PC-3 cells treated with specific SHBG siRNA grow relatively slower compared to the cells cultivated with control siRNA. (* means P <0.05). (D) Flowcytometry of CD44 and CD90 (left and right panel, respectively). While 10 nM DHT treatment for 48 hrs induces its expression in both cell lines for both genes (left parts of both panels), there is no CD44 and CD90 expression difference in these cells after specific SHBG siRNA knockdown compared to the siRNA control cells (right parts of both panels).
    Shbg Sirna Sc 44847, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shbg sirna sc-44847/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    shbg sirna sc-44847 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bi-10773/bi-44847  (Boehringer Ingelheim)
    90
    Boehringer Ingelheim bi-10773/bi-44847
    Representation of the 1:1 transport of sodium and glucose across the luminal membrane of the epithelial cells of the early part of the proximal tubule facilitated by <t>SGLT2</t>
    Bi 10773/Bi 44847, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bi-10773/bi-44847/product/Boehringer Ingelheim
    Average 90 stars, based on 1 article reviews
    bi-10773/bi-44847 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Stronger immunocytochemical staining of SHBG is shown in LNCaP and PC-3 cells treated with DHT (left panel, bar scale: 50 µm). Immunoblotting demonstrates higher levels of SHBG, Oct3/4 and Nanog expressions in the cells treated with DHT (right panel). (B) SHBG specific siRNA results. SHBG knockdown in both LNCaP and PC-3 cells was verified by immunoblotting (left panel); 10 nM DHT induces expressions of Oct3/4 and Nanog in the cells transfected with the siRNA control, but such an induction disappears in the cells transfected with the specific SHBG siRNA (right panel). (C) LNCaP and PC-3 cells treated with specific SHBG siRNA grow relatively slower compared to the cells cultivated with control siRNA. (* means P <0.05). (D) Flowcytometry of CD44 and CD90 (left and right panel, respectively). While 10 nM DHT treatment for 48 hrs induces its expression in both cell lines for both genes (left parts of both panels), there is no CD44 and CD90 expression difference in these cells after specific SHBG siRNA knockdown compared to the siRNA control cells (right parts of both panels).

    Journal: PLoS ONE

    Article Title: SHBG Is an Important Factor in Stemness Induction of Cells by DHT In Vitro and Associated with Poor Clinical Features of Prostate Carcinomas

    doi: 10.1371/journal.pone.0070558

    Figure Lengend Snippet: (A) Stronger immunocytochemical staining of SHBG is shown in LNCaP and PC-3 cells treated with DHT (left panel, bar scale: 50 µm). Immunoblotting demonstrates higher levels of SHBG, Oct3/4 and Nanog expressions in the cells treated with DHT (right panel). (B) SHBG specific siRNA results. SHBG knockdown in both LNCaP and PC-3 cells was verified by immunoblotting (left panel); 10 nM DHT induces expressions of Oct3/4 and Nanog in the cells transfected with the siRNA control, but such an induction disappears in the cells transfected with the specific SHBG siRNA (right panel). (C) LNCaP and PC-3 cells treated with specific SHBG siRNA grow relatively slower compared to the cells cultivated with control siRNA. (* means P <0.05). (D) Flowcytometry of CD44 and CD90 (left and right panel, respectively). While 10 nM DHT treatment for 48 hrs induces its expression in both cell lines for both genes (left parts of both panels), there is no CD44 and CD90 expression difference in these cells after specific SHBG siRNA knockdown compared to the siRNA control cells (right parts of both panels).

    Article Snippet: SHBG siRNA (sc-44847) and siRNA control (sc-33007) for transient transfection were obtained from Santa Cruz Biotechnology.

    Techniques: Staining, Western Blot, Knockdown, Transfection, Control, Expressing

    (A) Positive and negative control of SHBG in liver tissues. (B) Weak SHBG positivity is shown in a benign prostate tumor and strong SHBG immunoreactivity is revealed in a malignant Gleason score 8 cancer tissue. (C) Representative immunohistochemical images of different scores of prostate cancer samples are shown. Bar scale in all of the images is 150 µm.

    Journal: PLoS ONE

    Article Title: SHBG Is an Important Factor in Stemness Induction of Cells by DHT In Vitro and Associated with Poor Clinical Features of Prostate Carcinomas

    doi: 10.1371/journal.pone.0070558

    Figure Lengend Snippet: (A) Positive and negative control of SHBG in liver tissues. (B) Weak SHBG positivity is shown in a benign prostate tumor and strong SHBG immunoreactivity is revealed in a malignant Gleason score 8 cancer tissue. (C) Representative immunohistochemical images of different scores of prostate cancer samples are shown. Bar scale in all of the images is 150 µm.

    Article Snippet: SHBG siRNA (sc-44847) and siRNA control (sc-33007) for transient transfection were obtained from Santa Cruz Biotechnology.

    Techniques: Negative Control, Immunohistochemical staining

    Comparison of clinical and pathologic characteristics by tumor SHBG intensity.

    Journal: PLoS ONE

    Article Title: SHBG Is an Important Factor in Stemness Induction of Cells by DHT In Vitro and Associated with Poor Clinical Features of Prostate Carcinomas

    doi: 10.1371/journal.pone.0070558

    Figure Lengend Snippet: Comparison of clinical and pathologic characteristics by tumor SHBG intensity.

    Article Snippet: SHBG siRNA (sc-44847) and siRNA control (sc-33007) for transient transfection were obtained from Santa Cruz Biotechnology.

    Techniques: Comparison

    Representation of the 1:1 transport of sodium and glucose across the luminal membrane of the epithelial cells of the early part of the proximal tubule facilitated by SGLT2

    Journal: Diabetes Therapy

    Article Title: Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes

    doi: 10.1007/s13300-011-0004-1

    Figure Lengend Snippet: Representation of the 1:1 transport of sodium and glucose across the luminal membrane of the epithelial cells of the early part of the proximal tubule facilitated by SGLT2

    Article Snippet: Candidate SGLT2 inhibitors Manufacturers: Johnson & Johnson/Tanabe Seiyaku Co. Ltd ( Japan) (T-1095); Sanofi-Aventis (AVE-2268); GlaxoSmithKline (remogliflozin/KGT 1681/sergliflozin); Wyeth (WAY-123783); Astellas Pharma Inc (ASP 1941/YM-543); Boehringer Ingelheim GmbH (BI-10773/BI-44847); Boehringer Ingelheim, GmbH/Ajinomoto (canagliflozin); Johnson & Johnson/Tanabe Mitsubishi (TA-7284/JNJ 28431754); Bristol-Myers Squibb Co/AstraZeneca (dapagliflozin); Lexicon (LX 4211); Isis Pharmaceuticals (ISIS 388626); Roche/Chugai (R7201/CSG452); Pfizer (PF-04971729).

    Techniques: Membrane

    Candidate SGLT2 inhibitors Manufacturers: Johnson & Johnson/Tanabe Seiyaku Co. Ltd ( Japan) (T-1095); Sanofi-Aventis (AVE-2268); GlaxoSmithKline (remogliflozin/KGT 1681/sergliflozin); Wyeth (WAY-123783); Astellas Pharma Inc (ASP 1941/YM-543); Boehringer Ingelheim GmbH (BI-10773/BI-44847); Boehringer Ingelheim, GmbH/Ajinomoto (canagliflozin); Johnson & Johnson/Tanabe Mitsubishi (TA-7284/JNJ 28431754); Bristol-Myers Squibb Co/AstraZeneca (dapagliflozin); Lexicon (LX 4211); Isis Pharmaceuticals (ISIS 388626); Roche/Chugai (R7201/CSG452); Pfizer (PF-04971729). Candidate molecules have also been registered by Kissei, Taisho, Theracos, and Daiichi Sankyo. NA; not applicable.

    Journal: Diabetes Therapy

    Article Title: Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes

    doi: 10.1007/s13300-011-0004-1

    Figure Lengend Snippet: Candidate SGLT2 inhibitors Manufacturers: Johnson & Johnson/Tanabe Seiyaku Co. Ltd ( Japan) (T-1095); Sanofi-Aventis (AVE-2268); GlaxoSmithKline (remogliflozin/KGT 1681/sergliflozin); Wyeth (WAY-123783); Astellas Pharma Inc (ASP 1941/YM-543); Boehringer Ingelheim GmbH (BI-10773/BI-44847); Boehringer Ingelheim, GmbH/Ajinomoto (canagliflozin); Johnson & Johnson/Tanabe Mitsubishi (TA-7284/JNJ 28431754); Bristol-Myers Squibb Co/AstraZeneca (dapagliflozin); Lexicon (LX 4211); Isis Pharmaceuticals (ISIS 388626); Roche/Chugai (R7201/CSG452); Pfizer (PF-04971729). Candidate molecules have also been registered by Kissei, Taisho, Theracos, and Daiichi Sankyo. NA; not applicable.

    Article Snippet: Candidate SGLT2 inhibitors Manufacturers: Johnson & Johnson/Tanabe Seiyaku Co. Ltd ( Japan) (T-1095); Sanofi-Aventis (AVE-2268); GlaxoSmithKline (remogliflozin/KGT 1681/sergliflozin); Wyeth (WAY-123783); Astellas Pharma Inc (ASP 1941/YM-543); Boehringer Ingelheim GmbH (BI-10773/BI-44847); Boehringer Ingelheim, GmbH/Ajinomoto (canagliflozin); Johnson & Johnson/Tanabe Mitsubishi (TA-7284/JNJ 28431754); Bristol-Myers Squibb Co/AstraZeneca (dapagliflozin); Lexicon (LX 4211); Isis Pharmaceuticals (ISIS 388626); Roche/Chugai (R7201/CSG452); Pfizer (PF-04971729).

    Techniques:

    Clinical status of SGLT2 molecules

    Journal: Diabetes Therapy

    Article Title: Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes

    doi: 10.1007/s13300-011-0004-1

    Figure Lengend Snippet: Clinical status of SGLT2 molecules

    Article Snippet: Candidate SGLT2 inhibitors Manufacturers: Johnson & Johnson/Tanabe Seiyaku Co. Ltd ( Japan) (T-1095); Sanofi-Aventis (AVE-2268); GlaxoSmithKline (remogliflozin/KGT 1681/sergliflozin); Wyeth (WAY-123783); Astellas Pharma Inc (ASP 1941/YM-543); Boehringer Ingelheim GmbH (BI-10773/BI-44847); Boehringer Ingelheim, GmbH/Ajinomoto (canagliflozin); Johnson & Johnson/Tanabe Mitsubishi (TA-7284/JNJ 28431754); Bristol-Myers Squibb Co/AstraZeneca (dapagliflozin); Lexicon (LX 4211); Isis Pharmaceuticals (ISIS 388626); Roche/Chugai (R7201/CSG452); Pfizer (PF-04971729).

    Techniques: